The omega ratio
that quietly tracks
mortality.

Omega-6 and omega-3 are both essential polyunsaturated fatty acids: the body can’t make them, you have to eat them. They share metabolic pathways — the same enzymes (delta-5 and delta-6 desaturases) convert both into the longer-chain derivatives that drive inflammation (from omega-6) and resolve it (from omega-3). When the supply of omega-6 dominates the supply of omega-3, those enzymes preferentially process omega-6. The inflammatory branch of the system runs hot.

For most of human history, the dietary omega-6:omega-3 ratio sat somewhere around 4:1. The 20th-century pivot to seed oils — soybean, corn, canola, sunflower, safflower, all linoleic-acid-dominant — pushed the typical Western ratio above 20:1. There’s no controlled human RCT that randomized 100,000 people to different ratios for a decade. But there is the UK Biobank.

In 2024, Zhang et al. published in eLife a prospective cohort analysis of 85,425 UK Biobank participants, plasma fatty-acid panels measured at baseline, followed for a mean of 12.7 years.¹ The exposure: plasma omega-6:omega-3 ratio, split into quintiles. The endpoints: all-cause mortality, cardiovascular mortality, cancer mortality. The findings:

Cancer mortality: 14% higher in the highest-ratio quintile vs lowest. The dose-response was approximately monotonic across quintiles — the further the ratio shifted toward omega-6 dominance, the higher the mortality risk on all three endpoints.¹

The nuance that matters.

This is where the Zhang paper rewards a careful read. Looking at omega-6 and omega-3 individually, both were inversely associated with mortality — meaning higher omega-6 alone (with proportional omega-3) was associated with lower mortality, and higher omega-3 with even lower mortality.¹

The killer is not omega-6 in absolute terms. The killer is the ratio. A diet high in both omega-6 and omega-3 reads as protective. A diet high in omega-6 with collapsed omega-3 reads as sharply harmful. The seed-oil-dominant Western diet pushes the ratio in the wrong direction not by adding too much omega-6 in isolation, but by overwhelming the system’s omega-3 supply.

How this connects to the trial data.

The Zhang epidemiology doesn’t stand alone. It connects to the same mechanism documented in DiNicolantonio & O’Keefe’s Open Heart 2018 paper² — that elevated linoleic acid in tissue produces oxidized metabolites driving cardiovascular and inflammatory damage. And to Alvheim’s 2012 mouse work in Obesity,³ which showed that raising dietary linoleic acid from 1% to 8% of energy tripled endocannabinoid concentrations and induced obesity — while adding omega-3 reversed it. And to Ramsden’s separation, in Br J Nutr 2010,⁴ of n-6-specific PUFA trials (raised CHD events 13%) from mixed n-3/n-6 trials (lowered them 22%).

These are different study types — mechanistic, controlled animal, intervention RCT, prospective human cohort — converging on the same finding. The omega-6:omega-3 ratio is one of the cleaner population-level risk signals modern nutrition epidemiology has surfaced.

What this actually tells you.

For an industrial cooking-oil specifier, the actionable read is: the goal isn’t to eliminate omega-6 from the food supply. The goal is to rebalance the ratio — which at population scale means reducing the dominance of high-linoleic seed oils in default formulations and replacing them with lower-PUFA, higher-oleic alternatives.

HOPO does that without requiring an omega-3 supplement: typical fatty-acid composition is roughly ~55% oleic, ~13% PUFA, ~32% saturated. The PUFA fraction is largely linoleic acid, but the absolute quantity is roughly one-quarter what soybean or sunflower oil contributes per gram. Specifying it in place of seed oils moves the ratio in the right direction at the formulation level, before anyone has to think about supplementation.